MYASTHENIA GRAVIS 2
Edrophonium and Myasthenia Gravis
Overview of Edrophonium
Edrophonium is a medication used during the Tensilon test to diagnose myasthenia gravis.
Indications for administration:
Patients exhibit unexplained muscle weakness, difficulty in breathing, swallowing, speaking, and keeping their eyes open.
Mechanism of Action
Edrophonium is classified as an anticholinesterase medication.
Function:
It prevents the breakdown of acetylcholine at the neuromuscular junction, making more acetylcholine available at receptor sites.
Clinical Effects of Edrophonium
In Myasthenic Crisis:
Administration leads to increased muscle strength.
Improvement seen within several minutes where patients can speak, swallow, and breathe easier.
In Cholinergic Crisis:
Administration causes worsening of symptoms (decreased muscle strength and increased respiratory distress).
Additional acetylcholine is not needed in cholinergic crisis due to receptor saturation.
Antidote for Edrophonium
Atropine
An anticholinergic that reverses symptoms associated with cholinergic crisis.
Nursing Interventions during Edrophonium Testing
Before the test:
Report patient signs and symptoms.
Monitor response to edrophonium after administration.
Record improvements to aid neurologists in diagnosis and treatment planning.
Post-administration:
Patient may continue to exhibit muscle weakness as the medication effect wanes.
Continuous cardiac monitoring is essential.
Keep atropine and resuscitation equipment accessible.
Nursing Care for Myasthenia Gravis Patients
Respiratory Monitoring:
Observe respiratory status (efforts, rates).
Ask patients about difficulty breathing.
Look for signs of shortness of breath during conversations.
Neuromuscular Function Assessment:
Perform head-to-toe assessment, focusing on cranial nerves.
Assess for any cranial nerve weakness, double vision, slurred speech, and facial expressions.
Monitor strength in limbs and ability to swallow.
Involve speech pathologist as needed for swallowing assessments.
Risk for Aspiration:
Elevate head of bed >30 degrees during meals.
Consider the use of feeding tubes if swallowing difficulties are severe.
Fall Prevention:
Assist with ambulation due to visual impairments and muscle weakness.
Recommend caution if patient demonstrates double vision or severe weakness.
Patient Education on Nutrition:
Recommend small meals to reduce chewing effort.
Suggest larger meals in the morning when muscle strength is greatest.
Advise taking anticholinesterase medications 30 minutes to 1 hour prior to meals.
Options for easier chewing/swallowing include thickened liquids and soft foods (e.g. soups vs. raw vegetables).
Treatment and Medications for Myasthenia Gravis
No cure
Cholinesterase Inhibitors:
Pyridostigmine is a commonly prescribed anticholinesterase medication.
Take medications around meal times for maximum efficiency.
Risk of Crisis:
Correct dosage is crucial to prevent myasthenic or cholinergic crisis symptoms.
Signs and Symptoms of Cholinergic Crisis:
Symptoms mirror overstimulation of the parasympathetic nervous system:
Pupil constriction, bronchoconstriction, increased salivation, GI cramping, diarrhea, bladder incontinence, bradycardia, severe muscle weakness, respiratory failure.
Be careful with succinylcholine and pancuronium, succ mimic acetylcholine and depolarise motor endplate causes paralysis , pan completely block ACHRs preventing ACH from binding
Other Medications:
Corticosteroids to reduce immune response.
Stronger immunosuppressive therapies may be prescribed.
Surgical and Advanced Treatment Options
Thymectomy:
Surgical removal of the thymus gland can provide symptom relief but is not a cure.
Plasmapheresis and IV Immunoglobulins:
Used in severe cases and involves filtering blood to remove antibodies attacking receptors.
Provides temporary relief of symptoms, lasting weeks to months.